Direct Answer
DaVita Inc. (NYSE: DVA) is the largest dialysis provider in the United States, operating over 3,100 outpatient kidney care centers serving approximately 200,000 patients with end-stage kidney disease. Dialysis patients require treatment three times per week for life, creating a highly recurring, non-discretionary revenue stream. Approximately 90% of U.S. dialysis patients have Medicare as their primary payer due to a 1972 law, making DaVita's revenue heavily dependent on federal reimbursement rates. DaVita and Fresenius Medical Care together constitute a duopoly in U.S. dialysis services.
Company Snapshot
| Ticker | DVA (NYSE) |
|---|---|
| Sector | Health Care / Health Care Facilities |
| Headquarters | Denver, CO |
| Fiscal Year End | December 31 |
| SEC CIK | 0000927066 |
| Revenue (FY2024) | ~$12.8 billion |
| Centers | 3,100+ outpatient dialysis centers in the U.S. and internationally |
| Key Metrics | Treatments per day, revenue per treatment, Medicare rate changes, patient count, home dialysis growth |
What DaVita Does
Dialysis is the process of filtering waste and excess fluid from the blood when the kidneys have failed to perform this function adequately. Patients with end-stage kidney disease (ESKD) must receive hemodialysis treatments at a clinic or perform home dialysis several times per week to survive. Without dialysis or a kidney transplant, ESKD is fatal within weeks. DaVita operates outpatient clinics where patients come in three times per week for approximately four hours per session. Each session requires specialized dialysis machines, disposable equipment, nursing staff, and physician oversight from a nephrologist.
The durability of DaVita's revenue comes from the medical necessity and frequency of treatment. Unlike an elective surgery or a discretionary medical visit, dialysis cannot be postponed or skipped. This creates an unusually predictable revenue stream for a healthcare company -- patient counts change gradually based on new ESKD diagnoses, patient deaths, and kidney transplants, but the revenue per patient is relatively predictable within any given year based on CMS reimbursement rates.
Berkshire Hathaway Ownership and GLP-1 Risk
Warren Buffett's Berkshire Hathaway became a major DaVita shareholder in the early 2000s and at various points has owned more than 40% of the company's shares outstanding. Berkshire's continued ownership has been a notable feature of DaVita's shareholder base for over two decades. More recently, the rise of GLP-1 weight-loss drugs (semaglutide, tirzepatide) has raised questions about DaVita's long-term patient volume. Since obesity and type 2 diabetes are the two leading causes of chronic kidney disease leading to ESKD, widespread GLP-1 adoption could potentially slow or reduce the growth of the ESKD patient pool over a 10-20 year horizon. This is an area of analytical uncertainty with significant disagreement about the magnitude and timeline of any effect.
Frequently Asked Questions
How does DaVita make money?
DaVita makes money by providing dialysis treatments to patients with end-stage kidney disease (ESKD) at its outpatient dialysis centers. Patients with kidney failure who do not receive a kidney transplant require dialysis three times per week for the rest of their lives, making dialysis a recurring, non-discretionary healthcare service. DaVita is paid per treatment by Medicare (which covers nearly all ESKD patients due to a 1972 Congressional act), Medicaid, and commercial insurers. The company also provides some home dialysis services and kidney care management programs for patients earlier in the progression of chronic kidney disease.
Why does Medicare cover dialysis for almost all patients?
In 1972, Congress passed legislation extending Medicare coverage to virtually all Americans with end-stage renal disease regardless of age, creating the ESRD program. This was an unusual expansion of Medicare, which normally covers people 65 and older or people with certain disabilities. The rationale was that kidney failure is a catastrophic, fatal condition with an effective treatment (dialysis or transplant), and dialysis was expensive enough that most patients could not afford it out of pocket. This federal program means that roughly 90% of DaVita's U.S. dialysis patients have Medicare coverage as their primary payer, giving the company a stable, government-guaranteed revenue source but also making it highly dependent on Medicare reimbursement rates set by Congress and CMS.
What is the competitive structure of the U.S. dialysis market?
The U.S. dialysis market is a duopoly. DaVita and Fresenius Medical Care (a German company) together operate roughly 70% of all U.S. outpatient dialysis centers. The remainder is divided among hospital-based dialysis programs, independent clinics, and smaller chains. This concentration exists because operating dialysis clinics requires specialized equipment, trained nursing staff, nephrologist relationships, and compliance with extensive Medicare certification requirements. High barriers to entry and the need for geographic density (patients must travel to clinics three times per week) have made the market difficult for new entrants. DaVita and Fresenius have a roughly equal split of the market, each with around 35% share.
How do reimbursement rate changes affect DaVita?
Since Medicare covers most DaVita patients, changes to the CMS bundled payment rate for dialysis treatments directly affect DaVita's revenue and profitability. The Medicare composite rate was overhauled in 2011 when Congress created a bundled payment system that included many previously separately billed drugs (particularly erythropoiesis-stimulating agents used to treat anemia in dialysis patients). Periodic rate updates from CMS can increase or decrease per-treatment revenue. The company faces ongoing lobbying and advocacy work to maintain or increase reimbursement. Commercial insurance patients generate significantly higher per-treatment revenue than Medicare patients, making the commercial insurance patient mix an important driver of profitability.
What are DaVita's main risks?
DaVita's main risks include: Medicare reimbursement rate pressure, since CMS sets the payment rates that govern most of DaVita's revenue and any reduction would directly reduce earnings; regulatory and compliance risk, as dialysis centers are extensively regulated and patient safety issues or billing practices can trigger government investigations and penalties; the long-term potential of GLP-1 drugs (like semaglutide and tirzepatide) to reduce obesity and type 2 diabetes, which are the leading causes of kidney disease, potentially slowing the growth of the ESKD patient population over time; home dialysis as a competitive and structural shift, which could reduce center-based volume; and Berkshire Hathaway's large ownership stake, which creates concentration of shareholder influence on corporate governance.